

Special Issue

Phase IV Research in Vaccine Epidemiology: Immunogenicity, Effectiveness, and Safety

Message from the Guest Editors

Phase-IV studies are crucial for increasing the confidence of the population in the vaccination, as well as for reviewing and assessing vaccination policies yet to be adopted. This Special issue is focused on the recent scientific and technical progresses made in this field. We want to collect contributions about the safety, effectiveness, and immunogenicity of vaccinations used in the “real world” in order to have a complete overview of the “vaccination in the real life”. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review, highlighting the topics described above.

Keywords

- vaccine strategies
- infectious diseases
- burden of disease
- morbidity and mortality
- vaccine compliance
- immunogenicity of vaccines
- safety of vaccines
- effectiveness of vaccination strategies

Guest Editors

Dr. Francesco Paolo Bianchi

Department of Biological Sciences and Human Oncology, University of Bari, Bari, Italy

Prof. Silvio Tafuri

Department of Biological Sciences and Human Oncology, University of Bari, Bari, Italy

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/69054

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).